

Impact of OTC Purchase and Utilization of Pain Killers in Rheumatoid Arthritis

Bharat V. Jain

Department of Pharmaceutics, Smt. Sharadchandrika Suresh Patil College of Pharmacy, Chopda, Maharashtra, India

Sandip R. Pawar

Department of Pharmaceutics, Smt. Sharadchandrika Suresh Patil College of Pharmacy, Chopda, Maharashtra, India

Atul A. Sabe

Department of Pharmaceutics, Smt. Sharadchandrika Suresh Patil College of Pharmacy, Chopda, Maharashtra, India

Jayesh T. Nimbalkar

Department of Pharmaceutical Chemistry, Smt. Sharadchandrika Suresh Patil College of Pharmacy, Chopda, Maharashtra, India

Abstract

Pain may be alleviated externally using topical therapies. It's true that topical pain relievers are effective. A lot of the time they also cause a thermal or a thermal sensation on the skin. The lack of systemic absorption means that topical therapies are safer than oral drugs. There are a variety of over-the-counter (OTC) topical creams, sprays, and gel pain relievers available for the treatment of arthritis and other types of physical pain. Both nonsteroidal anti-inflammatory drugs (NSAIDs) and capsaicin, the chemical responsible for chilli peppers' spiciness, may be used. Yet, NSAIDs are not without hazards and adverse effects. Prostaglandins are involved in a variety of processes in addition to pain. Yet, since NSAIDs lower prostaglandins in the body, the stomach lining may become more susceptible to injury from acid. Causes of stomach distress, ulcers, and internal bleeding may result from this. Additional potential NSAID side effects include hives, wheezing, which may be harmful for those with asthma; changes in renal function; and a rash. This study takes an indepth look at the use of pain killers in rheumatoid arthritis.

Keywords: *Protect, Prostaglandins, Damage, Wheezing, Vulnerable.*

INTRODUCTION

Symptoms of rheumatoid arthritis may be managed with anti-inflammatory drugs including ibuprofen and steroids. Yet, they are not effective in protecting the joints. They function well as a stopgap measure for severe pain until disease-modifying medicines take

effect. Inflammation in the body may be reduced by disease-modifying antirheumatic medications (DMARDs), protecting joints from injury and alleviating symptoms (Bhala, 2013)¹. Nevertheless, it may take a while (weeks) before they really begin to function. Until then, medications and steroids may help with the discomfort of rheumatoid arthritis.

One of the best over-the-counter treatments for osteoarthritis pain is nonsteroidal anti-inflammatory medicines (NSAIDs), say the American College of Rheumatology and the Arthritis Foundation. In addition to alleviating pain, NSAIDs also have anti-inflammatory effects.

Options include:

- (i) “ibuprofen (Motrin) tablets for all types of OA”
- (ii) “Creams and ointments containing NSAIDs for OA of the knee and hand”
- (iii) “naproxen (Aleve)”
- (iv) “aspirin”
- (v) “nabumetone (Refalen)”

Pain and inflammation may be alleviated with the help of NSAIDs since they act by lowering levels of chemicals in the body called prostaglandins. This helps alleviate discomfort and decrease joint swelling and inflammation (Van Walsem et. al., 2015)9.

Nonsteroidal anti-inflammatory drugs (NSAIDs) also lessen blood coagulation. If a person is at a high risk for a heart attack, for instance, they may take aspirin to thin their blood. Yet, excessive blood-thinning increases the danger of bleeding or bruising.

Another over-the-counter (OTC) medicine useful for arthritic pain management is acetaminophen (Tylenol).

The brain's perception of pain is decreased, allowing this medication to relieve discomfort. While it may alleviate discomfort, it will not diminish joint inflammation. So, the ACR/AF only gives their stamp of approval if you can't use nonsteroidal anti-inflammatory drugs. When used in excess, acetaminophen may cause serious side effects, such as a skin rash (Da Costa et al, 2017)2. The Reliable One Liver damage may occur through long-term use of

high doses or from mixing it with alcohol. Yet it's safe to use when expecting a child.

Herbs and supplements were used by some people to give treatment to OA pain, like:

- (i) Vit-D
- (ii) FishOil
- (iii) “glucosamine”

Nevertheless, they are not recommended by professionals since there is little data to prove their efficacy and some may combine with other medications or induce undesirable side effects.

AIMS AND OBJECTIVES

To study the Pros and Cons of non-steroidal anti-inflammatory drug (NSAIDs)

METHODOLOGY

To understand the purchase of over-the-counter drugs sold without a prescription.

Celecoxib, diclofenac, etoricoxib, ibuprofen, and naproxen are all nonsteroidal anti-inflammatory drugs (NSAIDs) that help alleviate joint discomfort. Around 15% of those who use them report an improvement in their symptoms, according to the research (Derry et al., 2016)4. Many variables, including the medicine and dosage, will influence the potential for adverse reactions and problems. When compared to other NSAIDs, celecoxib and etoricoxib are safer for the stomach. The risk of cardiovascular disorders like heart attacks may be somewhat increased by using NSAIDs, with the exception of acetylsalicylic acid (the substance in treatments like Aspirin). Naproxen has the lowest risk of this side effect, making it the best NSAID for those with rheumatoid arthritis and heart problems. Long-term usage of NSAIDs has been linked to the development of stomach ulcers. One's upper abdomen may hurt as a result of them. After eating, when stomach acid levels are highest, the agony is at its worst. Often patients with

stomach ulcers don't even know they have them until they develop major consequences like gastrointestinal haemorrhage (DGRh, 2019)⁵.

Inclusion Criteria

Higher Risk of Complications:

Those who: have a history of stomach ulcers or bleeding; have a weak immune system; smoke;

- (i) are older than 65,
- (ii) having a preexisting ailment, particularly a digestive disorder like Crohn's disease or ulcerative colitis,
- (iii) have a history of stomach problems such as gastritis (inflammation), ulcers, or bleeding,
- (iv) suffer from a *Helicobacter pylori* infection,
- (v) consume excessive amounts of alcohol,
- (vi) anticoagulants like warfarin or acetylsalicylic acid, which are used to treat cardiac conditions,
- (vii) do anything like antidepressant medication selective serotonin reuptake inhibitor (SSRI),
- (viii) either use corticosteroids (or "steroids"),
- (ix) use a combination of anti-inflammatory medications to combat discomfort.

Those with renal problems may also have adverse effects from NSAIDs. As a result, NSAIDs should be taken sparingly and not continuously, i.e., only for the short-term relief of severe pain. Avoid exceeding the maximum recommended daily dosage and utilise the lowest effective dose.

Using NSAIDs alongside medication meant to protect the lining of the stomach may significantly reduce the risk of issues affecting the gastrointestinal system. Proton pump

inhibitors like omeprazole and pantoprazole are among them (Fidahic et al, 2017)⁶. You may also try a topical lotion or cream with diclofenac or ibuprofen on the aching joint. As compared to taking pills, the potential for adverse consequences is much reduced in this scenario. Only under a doctor's watchful eye should any drug be consumed.

Acetaminophen (paracetamol), although effective in relieving pain, does nothing to reduce inflammation. Evidence suggests it is not as effective as nonsteroidal anti-inflammatory drugs (NSAIDs) for relieving the pain associated with rheumatoid arthritis (Hazlewood, van der Heijde and Bombardier, 2012)⁷. Liver and renal failure might occur with higher dosages. According to the directions on the box, adults shouldn't take more than 4 grammes (4,000 milligrammes) daily. This is the equivalent of eight 500 mg acetaminophen pills. It is also suggested that at least six hours pass between dosages. Thus, the maximum recommended daily dose is two 500 mg tablets spaced every six hours.

Anti-inflammatory and pain relieving steroid (glucocorticoid) drugs like prednisolone are helpful in these cases. They operate more effectively than NSAIDs and start acting quickly. These may bridge the gap until the primary treatment with disease-modifying medicines takes effect. They are useful in the short-term management of RA attacks as well. On the other hand, steroid usage should be limited to no more than three to six months at a time. This might be due, in part, to the fact that prolonged usage of the drug reduces its efficacy. Long-term steroid use is associated with a variety of potentially fatal adverse effects. There is a higher possibility of developing infections and bone fractures. Steroids, in addition to bone-protective nutrients like calcium and vitamin D, may assist those with osteoporosis keep their bone mass. Steroids might make symptoms worse if therapy is abruptly discontinued (Depont et al,

2007)11. The dosage should be decreased slowly instead. It is possible to inject steroids straight into the joints that are the most damaged. Total-body side effects are less likely to occur as a result. But, complications at the joint level, including an infection, cannot be ruled out entirely. A dearth of high-quality studies on the benefits and risks of these corticosteroid injections is unfortunate (Moore, 2003)17.

DISCUSSION OF FINDINGS

Impact of OTC Purchases: Most of the dangers associated with using nonsteroidal anti-inflammatory drugs (NSAIDs) are dose- and time-dependent, pharmacological. Even though there is a lot of conjecture regarding the potential dangers of low-dose "over-the-counter" NSAIDs, very little is known about how these drugs are actually used. The same holds true for the majority of nonsteroidal anti-inflammatory drugs available with a doctor's prescription.

It is possible that risk models for these medications established from clinical trials or observational research that excluded OTC-type consumption are not appropriate to real-world use.

Inhibitors of cyclo-oxygenase (COX), of which the so-called 'coxibs' are a subset, are used for a wide variety of conditions and patterns of use, from very short-term, intermittent use at low doses in common painful conditions like the common cold, influenza, headache, or menstrual pain to long-term, continuous use at high doses in chronic inflammatory diseases like rheumatoid arthritis.

Although NSAIDs have a wide variety of therapeutic and adverse effects, which is consistent with the widespread distribution of prostaglandins, gastrointestinal and cardiovascular adverse reactions have been of primary concern for NSAIDs in recent years; for both of these, the dose and duration

dependence of the risk has been demonstrated. Certain NSAIDs are available solely via prescription, while others may be purchased "over-the-counter" (OTC) under a variety of brand names and packaging sizes. While NSAIDs are often prescribed, little is understood about their actual use. Real-world POM NSAID usage is likely to be less continuous and longer duration than in randomised clinical studies, especially for chronic illnesses. In this case, it would explain why the actual occurrence rates are lower than predicted. Often, OTC NSAIDs are used by younger patients, at lesser dosages, for shorter periods of time, and for different reasons than POM NSAIDs.

As OTC NSAIDs are not often tracked in healthcare databases, very little is known about how often they are used, how much is purchased, or whether or not other risk factors are present while using these medications. Over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs) in France may be registered in healthcare databases and paid if a doctor prescribes them. Seventy percent of all ibuprofen sales might be at stake here. Many patients may seek their doctor for a prescription for these medications for future or ongoing usage to deal with chronic or reoccurring pain caused by conditions including osteoarthritis, migraines, or dysmenorrhea. Low-dose NSAIDs will also be administered to those who seek medical attention for flu or trauma. Our goal was to characterise individuals who were given OTC and POM NSAIDs using a sample from the database of the French healthcare system.

Long-term sickness registration, age at first NSAID prescription, and gender were included as demographic factors. With a diagnosis of an ALD, all disease-related medical costs are fully covered. Patients were classified as having a prevalent ALD if they were already listed with one prior to inclusion, or as having an incident

ALD if they were added to the registry after the fact.

Name and quantity of NSAIDs distributed, number and frequency of dispensing, number of defined daily doses (DDD) per dispensing, and total number of DDD dispensed over 2 years characterise exposure to NSAIDs. Drug Distribution Database information was gathered from the WHO Collaborating Centre for Drug Statistics. In cases where the DDD was unavailable, the daily dosage prescribed by the French national drug formulary of 2012 (VIDAL® dictionary, Paris) was utilised instead.

Previous research has shown that NSAID users are disproportionately young, with an average age of 40 for OTC users and 47 for POM users. In both groups, the rates of coexisting chronic conditions were low, as would be anticipated given the ages of the people who used OTC and prescription drugs. There were fewer coexisting illnesses in the younger OTC users compared to the older POM users. Most of these low-risk individuals will only be exposed to NSAIDs for a short period of time, therefore the likelihood of a substantial influence on cardiovascular risk or interaction with cardiovascular medicines seems minimal.

Other Approaches to Arthritis Relief

S. No.	Activity	Alternatives
1	Walking	Treadmill (without incline)
2	Cycling	Riding a stationary bike
3	Freestyle swimming	Water walking
4	Yoga	Modified Asanas
5	Tai chi	Flowing motions
6	Strength training	Build muscles

These have been discussed in detail below:

a) Walking: A treadmill (without an inclination) might be utilised for those who have trouble keeping their balance. Walking at

a moderate speed is a great low-impact workout that can be done anywhere.

b) In order to gradually increase strength, riding a stationary bike on the easiest setting is recommended. Riding a bike around the neighbourhood is a great way to get some exercise and avoid the stress of driving.

c) Freestyle swimming is a good water exercise since it offers a cardio and strength training workout at a moderate intensity. Water walking has several health benefits, including reducing joint stress and strengthening muscles. In many cases, this helps reduce hip discomfort and restores normal movement.

d) Yoga: When practised regularly, it may help strengthen muscles, reduce discomfort, and increase joint flexibility. If you're experiencing pain in your hips during yoga, tell your teacher so they can modify the pose for you. The best way to learn is to enrol in an introductory course.

e) Tai chi's gentle, flowing motions may help ease arthritic pain and improve balance. Stress may be reduced in a healthy and natural way using tai chi.

f) Strength training is a great way to reduce stress on your hip joints and enhance your balance. No more than two sessions of strength training per week are recommended to build muscles.

Tips that help relieve OA hip pain

(i) Pay attention to how your body reacts to your actions and modify them accordingly.

(ii) Maintain a low intensity level and focus on strengthening the muscles around the hips.

(iii) Increased discomfort prompts you to take a break for a while. Overusing your hip might be the cause of joint discomfort that persists long after you've stopped moving.

(iv) Try to get in some walks whenever you can throughout the day to keep your metabolism up.

(v) When hip pain strikes, many people go for nonprescription anti-inflammatory drugs.

(vi) We must all get enough sleep.

(vii) Take care of your weight; being overweight is a nuisance.

(viii) Participate in a health club or take an exercise class to keep your mind and body engaged and productive.

In addition, most healthcare databases have the same shortcomings, such as a lack of information on pharmacological indications and recommended dosage, and a scarcity of data about comorbidities, with the exception of long-term disorders. In nations where the dosage is determined by the prescription, this may be a serious problem. Products in France are sold in boxes containing a certain number of pills of a known potency. Total drug distribution volume (DDD) may be calculated with high accuracy. This allows us to extrapolate the more general indications for the medication's use; for example, it's highly unlikely that a prescription issued for only a few days' worth of treatment over a duration of two years is for rheumatoid arthritis or osteoarthritis, but rather for episodes of acute pain. In contrast to continuously used drugs like antiepileptics, antihypertensives, or lipid-lowering medications, the time of usage in relation to the time of administration may be inconsistent for NSAIDs since they are symptom-relieving drugs.

CONCLUSIONS

Over-the-counter NSAIDs are used in ways that make sense, given their traditional pain indications. Both OTC and prescription NSAID purchases in this research were much lower than what is typically supplied to patients in clinical studies. Much of the dangers associated

with NSAIDs come from the fact that people seldom purchase the quantities used in clinical studies. These use patterns should be considered when extrapolating the outcomes of clinical studies to the actual use and dangers of NSAIDs in the real world. It may be very speculative to attempt to extrapolate the risks seen in clinical studies to real-world applications. Obviously, more real-world research is required to precisely describe the true dangers of low-dose OTC or prescription NSAIDs.

References

- Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. *Lancet* 2013; 382(9894): 769-779.
- Da Costa BR, Reichenbach S, Keller N, Nartey L, Wandel S, Jüni P et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. *Lancet* 2017; 390(10090): e21-e33.
- Dachverband der Deutschsprachigen Wissenschaftlichen Osteologischen Gesellschaft (DVO). Prophylaxe, Diagnostik und Therapie der Osteoporose bei postmenopausalen Frauen und bei Männern (Leitlinie). AWMF-Registernr.: 183-001. 2017.
- Derry S, Conaghan P, Da Silva JA, Wiffen PJ, Moore RA. Topical NSAIDs for chronic musculoskeletal pain in adults. *Cochrane Database Syst Rev* 2016; (4): CD007400.
- Deutsche Gesellschaft für Rheumatologie (DGRh). Management der frühen rheumatoiden Arthritis (S3-Leitlinie). AWMF-Registernr.: 060-002.

December 18, 2019.

- Fidahic M, JelcicKadic A, Radic M, Puljak L. Celecoxib for rheumatoid arthritis. *Cochrane Database Syst Rev* 2017; (6): CD012095.
- Hazlewood G, van der Heijde DM, Bombardier C. Paracetamol for the management of pain in inflammatory arthritis: a systematic literature review. *J Rheumatol Suppl* 2012; 90: 11-16.
- Ofman JJ, Maclean CH, Straus WL, Morton SC, Berger ML, Roth EA et al. Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs. *Arthritis Rheum* 2003; 49(4): 508-518.
- Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E et al. Prevention of NSAID-induced gastroduodenal ulcers. *Cochrane Database Syst Rev* 2002; (4): CD002296
- Van Walsem A, Pandhi S, Nixon RM, Guyot P, Karabis A, Moore RA. Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis. *Arthritis Res Ther* 2015; 17: 66.
- Depont F, Fourrier A, Merliere Y, Droz C, Amouretti M, Begaud B, Benichou J, Moride Y, Blin P, Moore N. The CADEUS study: methods and logistics. *Pharmacoepidemiol Drug Saf*. 2007;16:571–580.
- Tramer MR, Moore RA, Reynolds DJ, McQuay HJ. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. *Pain*. 2000;85:169–182.
- Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowitz JB, Verburg KM, Geis GS. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. *JAMA*. 2000;284:1247–1255
- Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. *N Engl J Med*. 2000;343:1520–1528. 2 p following 28.
- Moore N, et al. Comment on ‘Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use’ Tramer. *Pain*. 2000;85:169–182. *Pain* 2001; 91: 401–2.
- Laharie D, Droz-Perroteau C, Benichou J, Amouretti M, Blin P, Begaud B, Guiard E, Dutoit S, Lamarque S, Moride Y, Depont F, Fourrier-Reglat A, Moore N. Hospitalizations for gastrointestinal and cardiovascular events in the CADEUS cohort of traditional or Coxib NSAID users. *Br J Clin Pharmacol*. 2010;69:295–302.
- Moore N. Place of OTC analgesics and NSAIDs in osteoarthritis. *Inflammopharmacology*. 2003;11:355–362.
- Moore N, Van Ganse E, Le Parc J, Wall R, Schneid H, Farhan M, Verrière F, Pelen F. The PAIN study: paracetamol, aspirin and ibuprofen new tolerability study. A large

scale, randomized clinical trial comparing the tolerability of aspirin, ibuprofen and paracetamol for short-term analgesia. Clin Drug Invest. 1999;18:89–98.

Martin-Latry K, Begaud B. Pharmacoepidemiological research using French reimbursement databases: yes we can! Pharmacoepidemiol Drug Saf. 2010;19:256–265.

Blin P, Lassalle R, Dureau-Pournin C, Ambrosino B, Bernard MA, Abouelfath A, Gin H, Le Jeune C, Pariente A, Droz C, Moore N. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database. Diabetologia. 2012;55:644–653.